Diabetes

A study published in Primary Care Diabetes pinpoints those at most risk and recommends education to improve the quality of life in diagnosed elderly patients.

Diagnosing diabetes based on traditional criteria has increasingly become unreliable.

Technology may not help teens with the emotional and physical weight of managing the disease, study results show.

GLP-1 receptor agonists, used to manage diabetes, are now being used for obesity in children and adolescents.

A new study from Dartmouth College found that patients maintained healthier blood sugar levels from April to September.

A new study in the New England Journal of Medicine found no significant difference in the number of children who received a T1D diagnosis between those with and without a SARS-CoV-2 infection.

This is the fourth approval for the drug stemming from the EMPOWER clinical trial program.

The American Diabetes Association's 2023 “Children and adolescents: standards of care in diabetes” highlights risk factors and treatment for type 1 and type 2 diabetes.

Presented as part of the Annual Meeting of the European Association for the Study of Diabetes (EASD) meeting, the study was designed as an analysis of the ASPREE trial.

Although investigators found a lack of strong evidence to support CGM programs in community pharmacy settings, studies in ambulatory care settings suggest that these programs are both feasible and beneficial.

Catch up on the latest pharmacy issues and trends with Doug Long, vice president of industry relations at IQVIA.

A study from Bavaria, Germany, found the frequency was higher among boys and children younger than the median age of 6.5 years during the pandemic.

Patients may not experience any early symptoms, making screening especially important.

Patients with diabetes taking a GLP-1 RA of any type had an increased risk of a new GERD diagnosis.

The approval was based on safety and efficacy data from 30 participants in 2 open-label, single-arm studies that received 1 to 3 infusions of donislecel.

Nearly two-thirds of individuals with T2D eventually develop atherosclerotic cardiovascular disease in the United States.

Over 37 million people in the United States have diabetes and are at risk for eye disease, with diabetic retinopathy (DR) being the leading cause of blindness in working-age adults.

Individuals with type 1 diabetes (T1D) had brain atrophy patterns equivalent to a brain age about 6 years older than their actual age.

Doing small spurts of exercise throughout the day provide numerous benefits.

What can CGM's provide for individuals who don't have diabetes?

Insulet plans to commercialize the new product in the United States starting in 2024.

The MiniMed 780G has been available in Europe since 2020.

Tirzepatide was associated with a greater reduction in hemoglobin A1c and body weight when compared to semaglutide. But with a current list price of $1,023 for a one-month supply, is tirzepatide (Mounjaro; Lilly) worth it?